China is systematically building healthcare technology dominance in Asia-Pacific by positioning genomics companies as essential infrastructure partners for developing economies. The HGP2 Rare Disease Coalition was launched in Kuala Lumpur on 10 May, uniting 10 countries under a common framework.
BGI Genomics, the Chinese company leading the initiative, is deploying high-throughput sequencing systems and AI-powered diagnostic platforms across Southeast Asia and South Asia.
China establishes institutional dependability through its affordable solutions and workforce development programs and full technical assistance that extends beyond individual technology agreements.
BGI is establishing national-level rare disease diagnostic centers, starting with the Ministry of Public Health of Thailand. The company’s iGeneT Pro platform automates genetic analysis in minutes, a capability that previously required years.
For low- and middle-income countries, this technology transforms diagnostic capacity overnight, but it also creates dependence on Chinese expertise and systems.
The strategic advantage lies in setting up the infrastructure. Once countries deploy BGI systems, retrain clinical staff, and integrate the platforms into health ministries, switching to competitors becomes operationally costly and politically complex. In this way technology becomes geopolitical leverage.
The training program for regional geneticists and physicians at the China Interpretation of Genetic Disease Training Workshop focuses on BGI’s proprietary systems. The partnership framework between the organizations establishes ethical standards and accessibility requirements while it creates technical standards that match Chinese technical standards.
The Deputy Director General of Health in Malaysia described the project as achieving precision health through a combination of genomics, artificial intelligence, advanced technology and strong policy framework.
